Purple Biotech ( (PPBT) ) just unveiled an update.
Purple Biotech Ltd. announced that its Annual Meeting of Shareholders, initially scheduled for April 15, 2025, was adjourned due to a lack of quorum. The meeting has been rescheduled for April 22, 2025, to provide additional time for shareholders to vote on the proposals. The company continues to solicit votes during the adjournment period, and previously submitted votes will remain valid unless revoked.
Spark’s Take on PPBT Stock
According to Spark, TipRanks’ AI Analyst, PPBT is a Underperform.
Purple Biotech’s overall stock score reflects significant financial distress, with zero revenue, persistent net losses, and negative cash flow. The technical analysis suggests a bearish trend, and valuation metrics are poor due to a negative P/E ratio and absence of dividend yield. The company needs strategic changes to address operational inefficiencies and improve revenue generation.
To see Spark’s full report on PPBT stock, click here.
More about Purple Biotech
Purple Biotech Ltd. operates in the biotechnology industry, focusing on the development of innovative cancer therapies. The company is based in Rehovot, Israel, and is involved in research and development activities aimed at advancing treatment options for cancer patients.
YTD Price Performance: -45.53%
Average Trading Volume: 19,959
Technical Sentiment Signal: Buy
Current Market Cap: $7.05M
Learn more about PPBT stock on TipRanks’ Stock Analysis page.